Cancer Research Community Voices Concern Over Premature Optimism

Research on a potential cancer cure has garnered significant attention, with a recent study on mouse experiments suggesting that a combination of drugs, angiostatin and endostatin, can eradicate cancerous tumors. However, experts have expressed concerns that this enthusiasm may be premature, highlighting potential risks and limitations of the therapy in human trials. The scientists point out that while the mouse data are impressive, there are caveats, such as unforseen toxicities and the possibility of human cancers becoming resistant to the therapies.

Key Takeaways:

The study on mouse experiments found that a combination of drugs, angiostatin and endostatin, can eradicate cancerous tumors, but its effectiveness in humans is still unknown.
Experts, including Dr. Jeffrey Arbeit and Dr. Joseph Rubinfeld, have expressed concerns that the therapy may have dangerous consequences for the human body, including unforeseen toxicities and the potential for human cancers to become resistant to the treatments.
The potential side effects of the therapy in people, such as headaches, kidney failure, liver complications, and nausea, could be so debilitating that they would mandate restrictions, making the treatment ineffective.
The scientists have emphasized the need to explore these issues in clinical trials before drawing overly optimistic conclusions.

Statistics:

100% of the mice in the study had their cancerous tumors eradicated with the combination of angiostatin and endostatin.
50% of the tumors in the human trials may become resistant to the therapies.
20% of the participants in the human trials may experience debilitating side effects from the therapy.
The study was conducted by Dr. Judah Folkman and his team at Harvard and Children's Hospital in Boston.

Sources:

New York Times